Close this search box.

Immunotherapies break into cold colorectal cancers at ASCO 2024

ARTICLE | Product Development

Data from Regeneron, Agenus and others highlight immuno-oncology progress in genetically stable colorectal cancer at ASCO 2024

By Lauren Martz, Executive Director, Biopharma Intelligence

May 31, 2024 10:06 PM UTC

Several immuno-oncology mechanisms on display at ASCO 2024 help the field inch closer to solving one of cancer immunotherapy’s biggest problems: achieving efficacy in cold solid tumors.

These mechanisms include bispecific antibodies that engage multiple T cell activation signals, immunocytokine therapies that couple checkpoint inhibition with immune stimulating cytokines, and combinations of innate immune activators. …